Matches in SemOpenAlex for { <https://semopenalex.org/work/W2084667813> ?p ?o ?g. }
- W2084667813 endingPage "2279" @default.
- W2084667813 startingPage "2272" @default.
- W2084667813 abstract "BackgroundUp to now, all tested Ebola virus vaccines have been based on the virus strain from the Zaire outbreak in 1976. We aimed to assess the safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine expressing the glycoprotein of the 2014 epidemic strain.MethodsWe did this randomised, double-blind, placebo-controlled, phase 1 clinical trial at one site in Taizhou County, Jiangsu Province, China. Healthy adults (aged 18–60 years) were sequentially enrolled and randomly assigned (2:1), by computer-generated block randomisation (block size of six), to receive placebo, low-dose adenovirus type-5 vector-based Ebola vaccine, or high-dose vaccine. Randomisation was pre-stratified by dose group. All participants, investigators, and laboratory staff were masked to treatment allocation. The primary safety endpoint was occurrence of solicited adverse reactions within 7 days of vaccination. The primary immunogenicity endpoints were glycoprotein-specific antibody titres and T-cell responses at day 28 after the vaccination. Analysis was by intention to treat. The study is registered with ClinicalTrials.gov, number NCT02326194.FindingsBetween Dec 28, 2014, and Jan 9, 2015, 120 participants were enrolled and randomly assigned to receive placebo (n=40), low-dose vaccine (n=40), or high-dose vaccine. Participants were followed up for 28 days. Overall, 82 (68%) participants reported at least one solicited adverse reaction within 7 days of vaccination (n=19 in the placebo group vs n=27 in the low-dose group vs n=36 in the high-dose group; p=0·0002). The most common reaction was mild pain at the injection site, which was reported in eight (20%) participants in the placebo group, 14 (35%) participants in the low-dose group, and 29 (73%) participants in the high-dose vaccine group (p<0·0001). We recorded no statistical differences in other adverse reactions and laboratory tests across groups. Glycoprotein-specific antibody titres were significantly increased in participants in the low-dose and high-dose vaccine groups at both day 14 (geometric mean titre 421·4 [95% CI 249·7–711·3] and 820·5 [598·9–1124·0], respectively; p<0·0001) and day 28 (682·7 [424·3–1098·5] and 1305·7 [970·1–1757·2], respectively; p<0·0001). T-cell responses peaked at day 14 at a median of 465·0 spot-forming cells (IQR 180·0–1202·5) in participants in the low-dose group and 765·0 cells (400·0–1460·0) in those in the high-dose group. 21 (18%) participants had mild fever (n=9 in the placebo group, n=6 in the low-dose group, and n=6 in the high-dose group). No serious adverse events were recorded.InterpretationOur findings show that the high-dose vaccine is safe and robustly immunogenic. One shot of the high-dose vaccine could mount glycoprotein-specific humoral and T-cell response against Ebola virus in 14 days.FundingChina National Science and Technology, Beijing Institute of Biotechnology, and Tianjin CanSino Biotechnology. Up to now, all tested Ebola virus vaccines have been based on the virus strain from the Zaire outbreak in 1976. We aimed to assess the safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine expressing the glycoprotein of the 2014 epidemic strain. We did this randomised, double-blind, placebo-controlled, phase 1 clinical trial at one site in Taizhou County, Jiangsu Province, China. Healthy adults (aged 18–60 years) were sequentially enrolled and randomly assigned (2:1), by computer-generated block randomisation (block size of six), to receive placebo, low-dose adenovirus type-5 vector-based Ebola vaccine, or high-dose vaccine. Randomisation was pre-stratified by dose group. All participants, investigators, and laboratory staff were masked to treatment allocation. The primary safety endpoint was occurrence of solicited adverse reactions within 7 days of vaccination. The primary immunogenicity endpoints were glycoprotein-specific antibody titres and T-cell responses at day 28 after the vaccination. Analysis was by intention to treat. The study is registered with ClinicalTrials.gov, number NCT02326194. Between Dec 28, 2014, and Jan 9, 2015, 120 participants were enrolled and randomly assigned to receive placebo (n=40), low-dose vaccine (n=40), or high-dose vaccine. Participants were followed up for 28 days. Overall, 82 (68%) participants reported at least one solicited adverse reaction within 7 days of vaccination (n=19 in the placebo group vs n=27 in the low-dose group vs n=36 in the high-dose group; p=0·0002). The most common reaction was mild pain at the injection site, which was reported in eight (20%) participants in the placebo group, 14 (35%) participants in the low-dose group, and 29 (73%) participants in the high-dose vaccine group (p<0·0001). We recorded no statistical differences in other adverse reactions and laboratory tests across groups. Glycoprotein-specific antibody titres were significantly increased in participants in the low-dose and high-dose vaccine groups at both day 14 (geometric mean titre 421·4 [95% CI 249·7–711·3] and 820·5 [598·9–1124·0], respectively; p<0·0001) and day 28 (682·7 [424·3–1098·5] and 1305·7 [970·1–1757·2], respectively; p<0·0001). T-cell responses peaked at day 14 at a median of 465·0 spot-forming cells (IQR 180·0–1202·5) in participants in the low-dose group and 765·0 cells (400·0–1460·0) in those in the high-dose group. 21 (18%) participants had mild fever (n=9 in the placebo group, n=6 in the low-dose group, and n=6 in the high-dose group). No serious adverse events were recorded. Our findings show that the high-dose vaccine is safe and robustly immunogenic. One shot of the high-dose vaccine could mount glycoprotein-specific humoral and T-cell response against Ebola virus in 14 days." @default.
- W2084667813 created "2016-06-24" @default.
- W2084667813 creator A5001457544 @default.
- W2084667813 creator A5006792547 @default.
- W2084667813 creator A5017541508 @default.
- W2084667813 creator A5018989202 @default.
- W2084667813 creator A5021333880 @default.
- W2084667813 creator A5021634528 @default.
- W2084667813 creator A5022611537 @default.
- W2084667813 creator A5034029886 @default.
- W2084667813 creator A5038863647 @default.
- W2084667813 creator A5041438685 @default.
- W2084667813 creator A5043379267 @default.
- W2084667813 creator A5049507373 @default.
- W2084667813 creator A5064919743 @default.
- W2084667813 creator A5070493054 @default.
- W2084667813 creator A5077645027 @default.
- W2084667813 creator A5082267036 @default.
- W2084667813 creator A5082815416 @default.
- W2084667813 creator A5087791435 @default.
- W2084667813 creator A5090911302 @default.
- W2084667813 creator A5091711709 @default.
- W2084667813 date "2015-06-01" @default.
- W2084667813 modified "2023-10-04" @default.
- W2084667813 title "Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial" @default.
- W2084667813 cites W1825594680 @default.
- W2084667813 cites W1992871632 @default.
- W2084667813 cites W1994675158 @default.
- W2084667813 cites W1997389064 @default.
- W2084667813 cites W2027894464 @default.
- W2084667813 cites W2046471199 @default.
- W2084667813 cites W2046730970 @default.
- W2084667813 cites W2075938204 @default.
- W2084667813 cites W2076340825 @default.
- W2084667813 cites W2076435512 @default.
- W2084667813 cites W2077149270 @default.
- W2084667813 cites W2092721627 @default.
- W2084667813 cites W2109986071 @default.
- W2084667813 cites W2115102869 @default.
- W2084667813 cites W2116152286 @default.
- W2084667813 cites W2122345805 @default.
- W2084667813 cites W2143749967 @default.
- W2084667813 cites W2155802193 @default.
- W2084667813 cites W2160674639 @default.
- W2084667813 cites W2162803282 @default.
- W2084667813 cites W2169962588 @default.
- W2084667813 cites W4210710163 @default.
- W2084667813 doi "https://doi.org/10.1016/s0140-6736(15)60553-0" @default.
- W2084667813 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25817373" @default.
- W2084667813 hasPublicationYear "2015" @default.
- W2084667813 type Work @default.
- W2084667813 sameAs 2084667813 @default.
- W2084667813 citedByCount "144" @default.
- W2084667813 countsByYear W20846678132015 @default.
- W2084667813 countsByYear W20846678132016 @default.
- W2084667813 countsByYear W20846678132017 @default.
- W2084667813 countsByYear W20846678132018 @default.
- W2084667813 countsByYear W20846678132019 @default.
- W2084667813 countsByYear W20846678132020 @default.
- W2084667813 countsByYear W20846678132021 @default.
- W2084667813 countsByYear W20846678132022 @default.
- W2084667813 countsByYear W20846678132023 @default.
- W2084667813 crossrefType "journal-article" @default.
- W2084667813 hasAuthorship W2084667813A5001457544 @default.
- W2084667813 hasAuthorship W2084667813A5006792547 @default.
- W2084667813 hasAuthorship W2084667813A5017541508 @default.
- W2084667813 hasAuthorship W2084667813A5018989202 @default.
- W2084667813 hasAuthorship W2084667813A5021333880 @default.
- W2084667813 hasAuthorship W2084667813A5021634528 @default.
- W2084667813 hasAuthorship W2084667813A5022611537 @default.
- W2084667813 hasAuthorship W2084667813A5034029886 @default.
- W2084667813 hasAuthorship W2084667813A5038863647 @default.
- W2084667813 hasAuthorship W2084667813A5041438685 @default.
- W2084667813 hasAuthorship W2084667813A5043379267 @default.
- W2084667813 hasAuthorship W2084667813A5049507373 @default.
- W2084667813 hasAuthorship W2084667813A5064919743 @default.
- W2084667813 hasAuthorship W2084667813A5070493054 @default.
- W2084667813 hasAuthorship W2084667813A5077645027 @default.
- W2084667813 hasAuthorship W2084667813A5082267036 @default.
- W2084667813 hasAuthorship W2084667813A5082815416 @default.
- W2084667813 hasAuthorship W2084667813A5087791435 @default.
- W2084667813 hasAuthorship W2084667813A5090911302 @default.
- W2084667813 hasAuthorship W2084667813A5091711709 @default.
- W2084667813 hasBestOaLocation W20846678131 @default.
- W2084667813 hasConcept C116675565 @default.
- W2084667813 hasConcept C126322002 @default.
- W2084667813 hasConcept C142724271 @default.
- W2084667813 hasConcept C159047783 @default.
- W2084667813 hasConcept C159654299 @default.
- W2084667813 hasConcept C168563851 @default.
- W2084667813 hasConcept C197934379 @default.
- W2084667813 hasConcept C203014093 @default.
- W2084667813 hasConcept C203092338 @default.
- W2084667813 hasConcept C204787440 @default.
- W2084667813 hasConcept C22070199 @default.
- W2084667813 hasConcept C27081682 @default.
- W2084667813 hasConcept C2777469322 @default.
- W2084667813 hasConcept C2778933410 @default.